Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Calidi Biotherapeutics, Inc. (CLDI : AMEX)

• Company Description    Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $1.62 Daily Weekly Monthly 20 Day Moving Average: 478,161 shares Shares Outstanding: 3.43 (millions) Market Capitalization: $5.55 (millions) Beta: 1.08 52 Week High: $46.68 52 Week Low: $1.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -67.86% -68.42% 12 Week -54.26% -58.45% Year To Date -88.27% -89.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4475 EXECUTIVE DRIVE SUITE 200 - SAN DIEGO,CA 92121 USA ph: 858-794-9600 fax: - ir@calidibio.com https://calidibio.com

• General Corporate Information    Officers Allan J. Camaisa - Chief Executive Officer and Chairman Andrew Jackson - Chief Financial Officer Alan Stewart - Director James Schoeneck - Director Scott Leftwich - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 320703408 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 3.43 Most Recent Split Date: 8.00 (0.08:1) Beta: 1.08 Market Capitalization: $5.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.25 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 88.16% vs. Previous Quarter: 7.91% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -5,152.88 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -175.92 03/31/25 - -188.55 12/31/24 - -256.02 Current Ratio 06/30/25 - 1.13 03/31/25 - 2.12 12/31/24 - 1.08 Quick Ratio 06/30/25 - 1.13 03/31/25 - 2.12 12/31/24 - 1.08 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.72 03/31/25 - 2.76 12/31/24 - 0.89 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.40 03/31/25 - 0.10 12/31/24 - 0.38 Debt-to-Capital 06/30/25 - 28.46 03/31/25 - 9.08 12/31/24 - 27.46

Powered by Zacks Investment Research ©